Endpoints News

Gilgamesh’s psychedelics pipeline gets $60M backing after AbbVie deal

Published

2 weeks ago

on

Investors have pumped $60 million into Gilgamesh Pharma to test a handful of psychedelics and other experimental neuroscience medicines that the biotech hasn’t yet promised to a partner.

The New York City biotech

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version